Table 7. Comparison of reported drug company payments to patient organisations in Sweden and the UK.

Selected variables	Sweden (2014–18)	UK (2012–16)
Population size	~ 10m	~ 65m
Value of payments, €	~ 6.4m	~ 65.1m
No. of payments	1337	4572
Median (IQR)	2 411 (1 024 to 4 569)	5 112 (686–11 984)
No. of companies	46	64
No. of patient organisations	77	508
Funding by top 10 companies	68%	69%
Public involvement	61%	31%
Support to patients	6%	6%
Research-related	1%	25%
Neoplasms	38%	36%
Endocrine, nutritional and metabolic	9%	11%
Infectious and parasitic	9%	8%